247 related articles for article (PubMed ID: 25159238)
1. Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension.
Sun BJ; Hwang E; Jang JY; Kim DH; Song JM; Kang DH
Am J Cardiol; 2014 Oct; 114(8):1234-7. PubMed ID: 25159238
[TBL] [Abstract][Full Text] [Related]
2. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
[TBL] [Abstract][Full Text] [Related]
3. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
5. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
Veselka J; Hájek P; Tomašov P; Tesař D; Brůhová H; Matějovič M; Branny M; Studenčan M; Zemánek D
Am J Cardiol; 2014 Feb; 113(3):446-51. PubMed ID: 24304551
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
[TBL] [Abstract][Full Text] [Related]
9. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
[TBL] [Abstract][Full Text] [Related]
10. The effect of infrequent low-dose rosuvastatin on the lipid profile.
Ibrahim C; Ban MR; Hegele RA
Can J Cardiol; 2014 Nov; 30(11):1392-5. PubMed ID: 25442436
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
Ko YG; Won H; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Bae JH; Lee S; Lim DS; Jang Y
Am J Cardiol; 2014 Jul; 114(1):29-35. PubMed ID: 24831577
[TBL] [Abstract][Full Text] [Related]
12. Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk.
Yang Y; Hwang E; Lee SA; Lee S; Kim DH; Song JM; Kang DH
J Cardiovasc Imaging; 2021 Jul; 29(3):255-262. PubMed ID: 34080332
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
[TBL] [Abstract][Full Text] [Related]
14. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension.
Galderisi M; D'Errico A; Sidiropulos M; Innelli P; de Divitiis O; de Simone G
J Hypertens; 2009 Oct; 27(10):2108-15. PubMed ID: 19564794
[TBL] [Abstract][Full Text] [Related]
15. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
[TBL] [Abstract][Full Text] [Related]
16. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension.
Galderisi M; Cicala S; Caso P; De Simone L; D'Errico A; Petrocelli A; de Divitiis O
Am J Cardiol; 2002 Oct; 90(8):860-4. PubMed ID: 12372574
[TBL] [Abstract][Full Text] [Related]
17. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
18. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
20. Incremental value of pulse wave velocity in the determination of coronary microcirculatory dysfunction in never-treated patients with essential hypertension.
Ikonomidis I; Lekakis J; Papadopoulos C; Triantafyllidi H; Paraskevaidis I; Georgoula G; Tzortzis S; Revela I; Kremastinos DT
Am J Hypertens; 2008 Jul; 21(7):806-13. PubMed ID: 18497732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
